4//SEC Filing
Rhodes Jason P 4
Accession 0000950170-24-064725
CIK 0001818794other
Filed
May 23, 8:00 PM ET
Accepted
May 24, 5:10 PM ET
Size
5.8 KB
Accession
0000950170-24-064725
Insider Transaction Report
Form 4
Rhodes Jason P
Director
Transactions
- Award
Stock option (right to buy)
2024-05-22+25,133→ 25,133 totalExercise: $31.53Exp: 2034-05-21→ Common Stock (25,133 underlying)
Footnotes (2)
- [F1]This option was granted on May 22, 2024. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 22, 2025 or (ii) the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to continued service.
- [F2]The Reporting Person is a member of Atlas Venture Associates XI, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the option to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.
Documents
Issuer
Dyne Therapeutics, Inc.
CIK 0001818794
Entity typeother
Related Parties
1- filerCIK 0001577014
Filing Metadata
- Form type
- 4
- Filed
- May 23, 8:00 PM ET
- Accepted
- May 24, 5:10 PM ET
- Size
- 5.8 KB